<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04849286</url>
  </required_header>
  <id_info>
    <org_study_id>HTL0016878-103</org_study_id>
    <secondary_id>2018-002784-26</secondary_id>
    <nct_id>NCT04849286</nct_id>
  </id_info>
  <brief_title>Measurement of HTL0016878 in Cerebrospinal Fluid</brief_title>
  <official_title>A Phase 1, Open-label, Randomised, Single-centre, Single Oral Dose Study to Determine the Concentration of HTL0016878 in Cerebrospinal Fluid and Plasma in Healthy Male Subjects Following Dosing With HTL0016878 Oral Solution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heptares Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heptares Therapeutics Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, open-label, randomised, single oral dose study to determine the concentration of&#xD;
      HTL0016878 in CSF and plasma in healthy male subjects following dosing with HTL0016878 10 mg&#xD;
      or 20 mg oral solution&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 24 healthy subjects will be enrolled into 4 groups, with 6 subjects per group. Each&#xD;
      subject will be randomised to receive a single oral dose of 10 mg or 20 mg HTL0016878&#xD;
      solution and will have a single CSF sample taken via lumbar puncture at either 2 or 6 hours&#xD;
      post-dose. Pharmacokinetic blood sampling and safety measures will continue until 24 hours&#xD;
      post-dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2018</start_date>
  <completion_date type="Actual">December 7, 2018</completion_date>
  <primary_completion_date type="Actual">December 7, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of HTL0016878 in CSF</measure>
    <time_frame>2 hours</time_frame>
    <description>Pharmacokinetics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of HTL0016878 in CSF</measure>
    <time_frame>6 hours</time_frame>
    <description>Pharmacokinetics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of HTL0016878 in plasma Cmax</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Pharmacokinetics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of HTL0016878 in plasma AUC</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Pharmacokinetics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Emergent Adverse events</measure>
    <time_frame>Baseline up to 10 days post-dose</time_frame>
    <description>Safety and Tolerability</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg dose, CSF sample 2 hours post-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg dose, CSF sample 6 hours post-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg dose, CSF sample 2 hours post-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg dose, CSF sample 6 hours post-dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTL0016878</intervention_name>
    <description>Oral solution</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subject has a body mass index (BMI) of 18 to 32 kg/m2, inclusive. Healthy as determined by&#xD;
        a responsible physician, based on medical evaluation including medical history, physical&#xD;
        examination, concomitant medication, vital signs, 12-lead ECG, C-SSRS responses, and&#xD;
        clinical laboratory evaluations.&#xD;
&#xD;
        Willingness to comply with requirements or the trial, including contraception requirements.&#xD;
&#xD;
        Able to give fully informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Positive tests for hepatitis B &amp; C, HIV. Clinically relevant history of abnormal physical&#xD;
        or mental health. Clinically relevant abnormal laboratory results (including hepatic and&#xD;
        renal panels, complete blood count, chemistry or coagulation panel and urinalysis), 12-lead&#xD;
        ECG and vital signs, or physical findings.&#xD;
&#xD;
        History of severe adverse reactions or allergies, or history of an anaphylactic reaction to&#xD;
        prescription or non-prescription medication or food.&#xD;
&#xD;
        Drug or alcohol abuse. Smoking. Use of medication that inhibits CYP2D6. Participation in&#xD;
        other clinical trials of unlicensed medicines in the previous 3 months. Loss of more than&#xD;
        400 mL blood in the previous 3 months. Vital signs, QTcF interval or laboratory values&#xD;
        outside the acceptable range. Predicted poor and intermediate CYP2D6 metabolisers.&#xD;
        Clinically relevant abnormal findings at the screening assessment. History of epilepsy or&#xD;
        seizures. Clinically relevant abnormal medical history or concurrent medical condition&#xD;
        disease associated with cognitive impairment and/or psychosis. History of suicidal thoughts&#xD;
        or ideation, or any history of insomnia. Use of tobacco and/or nicotine containing products&#xD;
        within 90 days of dosing. Habitual and heavy consumption of caffeinated beverages.&#xD;
        Consumption of cranberry, pomegranate, star fruit, grapefruit, pomelos, exotic citrus&#xD;
        fruits or Seville oranges (including marmalade and juices made from these fruits) within 3&#xD;
        days before admission. Objection by General Practitioner&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9NQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 15, 2021</study_first_submitted>
  <study_first_submitted_qc>April 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>April 15, 2021</last_update_submitted>
  <last_update_submitted_qc>April 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cerebrospinal Fluid</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

